WO2007105171A3 - Killing of selected cells - Google Patents

Killing of selected cells Download PDF

Info

Publication number
WO2007105171A3
WO2007105171A3 PCT/IB2007/050849 IB2007050849W WO2007105171A3 WO 2007105171 A3 WO2007105171 A3 WO 2007105171A3 IB 2007050849 W IB2007050849 W IB 2007050849W WO 2007105171 A3 WO2007105171 A3 WO 2007105171A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
killing
present
targeted
inactivating
Prior art date
Application number
PCT/IB2007/050849
Other languages
French (fr)
Other versions
WO2007105171A2 (en
Inventor
Martin Roland Jensen
Liselotte Kahns
Original Assignee
Nannovation Biotech Aps
Martin Roland Jensen
Liselotte Kahns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nannovation Biotech Aps, Martin Roland Jensen, Liselotte Kahns filed Critical Nannovation Biotech Aps
Publication of WO2007105171A2 publication Critical patent/WO2007105171A2/en
Publication of WO2007105171A3 publication Critical patent/WO2007105171A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)

Abstract

The present invention relates to the field of targeted killing of cells appearing in a mixed population of cells. In particular, the present invention relates to targeted and selective killing of transplanted cells in vivo or of feeder/co-culture cells in cell culture systems in vitro. By use of nanotechnology this invention provide a new means of labelling cells in such a way that they may be selectively killed or inactivated when they are in admixture with cells it is intended not to kill. More precisely, the present invention describes ways for labelling cells with nanostructures that are designed to be capable of exerting a lethal or inactivating or inactivating influence on a cell - this allows for subsequent specific inactivation or killing of the labelled cells by use of convenient, non-invasive signalling technologies.
PCT/IB2007/050849 2006-03-13 2007-03-13 Killing of selected cells WO2007105171A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600356 2006-03-13
DKPA200600356 2006-03-13

Publications (2)

Publication Number Publication Date
WO2007105171A2 WO2007105171A2 (en) 2007-09-20
WO2007105171A3 true WO2007105171A3 (en) 2007-12-13

Family

ID=37198805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/050849 WO2007105171A2 (en) 2006-03-13 2007-03-13 Killing of selected cells

Country Status (1)

Country Link
WO (1) WO2007105171A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107858B2 (en) 2007-12-05 2015-08-18 Wisconsin Alumni Research Foundation Dendritic cell targeting compositions and uses thereof
DE102008030035A1 (en) 2008-06-18 2010-02-04 Technische Universität Dresden Stimulation of piezoelectric, pyroelectric or ferroelectric crystals forming electrical dipoles, to catalyze chemical surface reactions
US9096846B2 (en) * 2009-12-22 2015-08-04 Empire Technology Development Llc Separation of cultured cells
FR2955097B1 (en) * 2010-01-13 2012-04-13 Centre Nat Rech Scient USE OF SILICON NANOTUBES COMPRISING AT LEAST ONE FREE FILLING ATOM AS AN ELECTROMECHANICAL NANO-OSCILLATOR

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055520A1 (en) * 2001-12-28 2003-07-10 Psimei Pharmaceuticals Plc Delivery of neutron capture elements for neutron capture therapy
WO2004067508A2 (en) * 2003-01-24 2004-08-12 The Research Foundation Of State University Of Newyork Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
WO2004096190A1 (en) * 2003-04-30 2004-11-11 Yonsei University Composition comprising magnetic nanoparticle encapsulating magnetic material and drug with biodegradable synthetic polymer
WO2005032602A2 (en) * 2003-10-02 2005-04-14 Ut-Battelle, Llc Sers molecular probe for diagnostics and therapy
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055520A1 (en) * 2001-12-28 2003-07-10 Psimei Pharmaceuticals Plc Delivery of neutron capture elements for neutron capture therapy
WO2004067508A2 (en) * 2003-01-24 2004-08-12 The Research Foundation Of State University Of Newyork Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
WO2004096190A1 (en) * 2003-04-30 2004-11-11 Yonsei University Composition comprising magnetic nanoparticle encapsulating magnetic material and drug with biodegradable synthetic polymer
WO2005032602A2 (en) * 2003-10-02 2005-04-14 Ut-Battelle, Llc Sers molecular probe for diagnostics and therapy
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FERRARI, M: "Cancer Nanotechnology: Opportunities and Challenges", NATURE REVIEWS, CANCER, vol. 5, March 2005 (2005-03-01), pages 161 - 171, XP002406036 *
HIRSCH, L R ET AL.: "Nanoshell-mediated near-infrared thermal therapy of tumours under magnetic resonance guidance", PNAS, vol. 100, no. 23, 11 November 2003 (2003-11-11), pages 13549 - 13554, XP002406033 *
LIU, W-T: "Nanoparticles and Their Biological and Environmental Applications", J. BIOSCI. BIOENG., vol. 102, no. 1, 2006, pages 1 - 7, XP002406037 *
MOGHIMI, S M; HUNTER, A C; MURRAY, J C: "Nanomedicine: current status and future prospects", FASEB JOURNAL, vol. 19, March 2005 (2005-03-01), pages 311 - 330, XP002406032 *
PANKHURST, Q A; CONNOLLY, J; JONES, S K; DOBSON, J: "Applications of magnetic nanoparticles in biomedicine", J PHYS. D: APPL. PHYS., vol. 36, 2003, pages R167 - R181, XP002406035 *
WONG SHI KAM, N ET AL.: "Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer destruction", PNAS, vol. 102, no. 33, 16 August 2005 (2005-08-16), pages 11600 - 11605, XP002406034 *

Also Published As

Publication number Publication date
WO2007105171A2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ES2571355T3 (en) Culture system without feeder cells or xenocontaminants for human embryonic stem cells
AU2015213336B2 (en) Novel conjugates of CC-1065 analogs and bifunctional linkers
AU2015213344B2 (en) Novel CC-1065 analogs and their conjugates
UA98629C2 (en) Compounds and methods for kinase modulation
WO2005067498A3 (en) Bioreactor systems and disposable bioreactor
SG179488A1 (en) Virus like particle purification
MX2009013706A (en) Multipotent/pluripotent cells and methods.
ATE554725T1 (en) SURGICAL ARTICLES FOR THE TREATMENT OF PELVIC DISEASES
MX2015004342A (en) Solutions and methods of making solutions to kill or deactivate spores, microorganisms, bacteria and fungus.
MX2009002496A (en) Combinations containing a 4-acylaminopyridine derivative.
EP2495310A3 (en) Microscale micropatterned engineered in vitro tissue
AU2007278899A8 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
MX2009012043A (en) Cytotoxic t cell activator comprising ep4 agonist.
MX2011012740A (en) Hive-mounted disseminator device.
WO2007081878A3 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
TNSN08400A1 (en) Organic compounds and their uses
WO2008064345A3 (en) Microorganism killing compounds
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
WO2007105171A3 (en) Killing of selected cells
WO2010025402A3 (en) Methods and apparatuses for plant aeration
IN2012DN03178A (en)
DE202007000949U1 (en) Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
MX2007012346A (en) Capsules containing seminal material for artificial insemination.
PL1729732T3 (en) Anionic hydrogel matrices with ph dependent modified release as drug carriers

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07735100

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07735100

Country of ref document: EP

Kind code of ref document: A2